Projekteja vuodessa
Abstrakti
Semi-solid extrusion (SSE) 3D printing enables flexible designs and dose sizes to be printed on demand and is a suitable tool for fabricating personalized dosage forms. Controlled Expansion of Supercritical Solution (CESS®) is a particle size reduction technology, and it produces particles of a pure active pharmaceutical ingredient (API) in a dry state, suspendable in the printing ink. In the current study, as a model API of poorly water-soluble drug, nanoformed piroxicam (nanoPRX) prepared by CESS® was accommodated in hydroxypropyl methylcellulose- or hydroxypropyl cellulose-based ink formulations to warrant the printability in SSE 3D printing. Importantly, care must be taken when developing nanoPRX formulations to avoid changes in their polymorphic form or particle size. Printing inks suitable for SSE 3D printing that successfully stabilized the nanoPRX were developed. The inks were printed into films with escalating doses with exceptional accuracy. The original polymorphic form of nanoPRX in the prepared dosage forms was not affected by the manufacturing process. In addition, the conducted stability study showed that the nanoPRX in the prepared dosage form remained stable for at least three months from printing. Overall, the study rationalizes that with nanoparticle-based printing inks, superior dose control for the production of personalized dosage forms of poorly water-soluble drugs at the point-of-care can be achieved.
Alkuperäiskieli | Englanti |
---|---|
Artikkeli | 106497 |
Sivumäärä | 14 |
Julkaisu | European Journal of Pharmaceutical Sciences |
Vuosikerta | 188 |
DOI - pysyväislinkit | |
Tila | Julkaistu - 1 syysk. 2023 |
OKM-julkaisutyyppi | A1 Julkaistu artikkeli, soviteltu |
Sormenjälki
Sukella tutkimusaiheisiin 'Personalizing oral delivery of nanoformed piroxicam by semi-solid extrusion 3D printing'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.Laitteet
-
Åbo Akademi Functional Printing Center
Toivakka, M. (PI), Rosenholm, J. (PI), Anttu, N. (PI), Bobacka, J. (PI), Huynh, T. P. (PI), Peltonen, J. (PI), Wang, X. (PI), Wilen, C.-E. (PI), Xu, C. (PI), Zhang, H. (PI) & Österbacka, R. (PI)
Faculty of Science and EngineeringLaitteistot/tilat: Laitos
Projektit
- 1 Päättynyt
-
AMBioPharma: Centre for Additive Manufacturing for Life Science and Pharmaceutical Industry
Rosenholm, J. (Vastuullinen tutkija), Xu, C. (Vastuullinen tutkija), Wang, X. (CoI) & Palo, M. (CoI)
01/09/21 → 31/08/23
Projekti: EU